Dogmas and Controversies in Hematologic Malignancies: West Coast Symposium

San Diego, CA US
March 29, 2024 to March 30, 2024

This CME-accredited activity, Dogmas and Controversies in Hematologic Malignancies: West Coast Symposium, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute leukemias, myeloproliferative neoplasms and multiple myeloma.

The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of recent advances along with scientific debates and panel-based discussions focusing on controversies in the management of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference will highlight a multidisciplinary approach and the integration of new advances in patient-centered care. Physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals will be updated on the the latest updates in Hematologic Malignancies.

 

Target Audience

  • Cancer care professionals
  • Medical Oncologists and Hematologists
  • Radiation oncologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

Organizing Committee 

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chairs: 

Alexey Danilov, MD, PHD- City of Hope

Thomas Martin, MD- UCSF Helen Diller Medical Center

Vinod Pullarkat MD- City of Hope

HOTEL INFORMATION

The Westin San Diego Gaslamp Quarter

Booking Link: https://book.passkey.com/go/BinaytaraFoundation

Room Cut-Off Date: Thursday, March 7, 2024 for discounted rate of $235 a night.

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
  2. Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
  3. Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors 
  4. Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal.

You may also be interested in

Summit on Cancer Health Disparities (SCHD24)

This annual oncology conference, The Summit on Cancer Health Disparities (SCHD24), is one of the largest gatherings of cancer care professionals interested in cancer health disparities with a focus on achieving health equity.
Course summary
Available credit: 
  • 9.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 9.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.
Course opens: 
11/02/2023
Course expires: 
06/21/2024
Event starts: 
03/29/2024 - 2:00pm PDT
Event ends: 
03/30/2024 - 4:30pm PDT
Cost:
$350.00
Add to calendar: 

DAY 1 - March 29th, 2024

All times are listed in Pacific Time (PT)

01:00 PM – 02:00 PM  Registration/Networking/Exhibits

02:00 PM – 02:15 PM  Welcome

02:15 PM – 03:45 PM  Session I - Non-Hodgkin's Lymphoma

Session Chairs: Alexey Danilov, MD, PHD & Krish Patel, MD

02:15 PM – 02:35 PM  Mantle Cell Lymphoma: Is it trying to become CLL? - Tycel Phillips, MD

02:35 PM – 02: 50 PM  DLBCL – Shifting landscape in 1st and 2nd line - James Godfrey, MD

02:50 PM – 03:05 PM  What is new in indolent NHL (FL, MZL)? - Geoffrey Shouse, DO, PhD

03:05 PM – 03: 25 PM  Debate: CAR-T versus bi-Specifics in DLBCL - Mazyar Shadman, MD, MPH & Krish Patel, MD

03:25 PM – 03:45 PM  Panel Discussion 

03:45 PM – 04:00 PM  Break & Exhibits

04:00 PM – 05:30 PM  Session II - Leukemia

Session Chairs: Vinod Pullarkat, MD & Neil Shah, MD, PhD

04:00 PM – 04:20 PM  Does anyone still need 7+ 3? Optimal use of venetoclax regimens in AML - Gabriel Mannis, MD

04:20 PM – 04:40 PM  The challenge of TP53 mutated AML - Brian Ball, MD

04:40 PM – 05:00 PM  Therapy related leukemias: Is it all bad news? - Vinod Pullarkat, MD

05:00 PM – 05:20 PM  Treatment milestones and treatment free remission in CML - Neil Shah, MD, PhD

05:20 PM – 05:30 PM  Panel discussion

05:30 PM – 06:30 PM  Reception/Networking

DAY 2 - March, 30th, 2024

7:00 AM – 8:00 AM  Registration, Breakfast, & Exhibits 

08:00 AM – 09:30 AM  Session III - Myeloma

Session Chairs: Thomas Martin, MD

08:00 AM –08:15 AM  Smoldering Myeloma - (when) are we treating? If yes, then How? - Shaji Kumar, MD

08:15 AM – 08:30 AM  Frontline therapy: TE, TI - should everyone get a CD38 Ab as part of induction - Rahul Banerjee, MD, FACP

08:30 AM – 8:45 AM  Maintenance after frontline therapy: Len or doublets/triplets - Aaron Rosenberg, MD, MS 

08:45 AM – 9:10 AM  Debate: MRD - need to drive response to MRD negativity and change based on MRD versus MRD; why check?? Not ready for prime time - Murali Janakiram, MD, MS & Surbhi Sidana, MD 

09:10 AM – 09:30 AM  Panel Discussion

09:30 AM – 10:00 AM  Break & Exhibits

10:00 AM – 11:30 AM  Session IV - Leukemia

Session Chairs: Vinod Pullarkat, MD & Lori Muffly, MD, MS

10:00 AM – 10:15 AM  Myeloproliferative neoplasms: Sequencing novel agents and stem cell transplantation - Rachel Salit, MD

10:15 AM – 10:30 AM  High risk MDS: Anything better than azacytidine? - Bart Scott, MD

10:30 AM – 10:45 AM  Ethnic variability and socioeconomic barriers to acute leukemia therapy - Elisa Quiroz, MD

10:45 AM – 1:15 AM  Debate: Consolidation therapy for ALL in the not so young adult, Immunotherapy vs. Stem Cell Transplantation - Ibrahim Aldoss, MD & Lori Muffly, MD, MS

11:15 AM –11:30 AM  Panel Discussion

11:30 AM – 12:00 PM  Session V - Global Oncology 

Improving Access to Hematology and Oncology in LMIC - Binaytara Foundation's Approach - Binay Shah, MD

12:00 PM – 01:00 PM  Lunch & Exhibits

Product Theater Sponsored by Johnson & Johnson in Santa Fe Room

Topic: TALVEY Overview & Darzalex Duration of Therapy

Speaker: Jessica Sexton, PharmD, BCOP- Senior Medical Liaison @ Johnson & Johnson

*Non CME Activity*

01:00 PM – 02:30 PM  Session VI - Myeloma

Session Chairs: Amrita Krishnan, MD

01:00- 01:15 PM  Immunotherapy for MM - Present and future - Thomas Martin, MD

01:15 PM – 1:35 PM  Debate: TCEs before CARs (Save CARs for later) versus CARs drive fast and first - bites happen later - Amrita Krishnan, MD & Ajai Chari, MD

01:35 PM – 1:50 PM  Complications: CRS-ICANS-Late Neuro-Infection - Anupama Kumar, MD

01:50 PM – 2:05 PM  Next Generation CAR-T cells - Arun Wiita, MD, PhD

02:05 PM – 2:15 PM  What's the latest in Amyloidosis - Michaela Liedtke, MD

02:15 PM – 02:30 PM  Panel Discussion 

02:30 PM – 03:00 PM  Break & Exhibits

03:00 PM – 04:30 PM  Session VII - Hodgkin's Lymphoma and CLL

Session Chairs: Alexey Danilov, MD, PHD & Aaron Goodman, MD

03:00 PM- 03:20 PM  How I treat HL - Ranjana Advani, MD

03:20 PM- 03:35 PM  Pathogenesis of Richters syndrome - Lili Wang, MD, PhD

03:35 PM- 03:55 PM  Debate 1: BTKi versus BCL2i in frontline therapy of CLL - Bita Fakhri, MD, MPH & Michael Choi, MD

03:55 PM- 04:15 PM  Debate 2: POST-BTKi: Future belongs to Non-covalents and Degraders; Future belongs to Bi-specifics and cell therapy - Tanya Siddiqi, MD & Catherine Coombs, MD

04:15 PM- 04:30 PM  Panel Discussion 

04:30 PM Adjourn

The Westin San Diego Gaslamp Quarter
910 Broadway Cir,
San Diego, CA 92101
United States

Booking Link: https://book.passkey.com/go/BinaytaraFoundation

Room Cut-Off Date: Thursday, March 7, 2024 for discounted rate of $235 a night.


 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Alexey Danilov, MD, PhD

has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Grant Or Contract) with Nurix;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Grant Or Contract) with MEI;.

Thomas Martin, MD

has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with GSK;.

Vinod Pullarkat, MD, MRCP

has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with jazz;.
has a financial relationship (Independent contractor) with rigel;.
has a financial relationship (Independent contractor) with amgen;.
has a financial relationship (Independent contractor) with sobi;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with sanofi;.
Speaker/Topic Presenter(s)

Ranjana Advani, Professor of Medicine at Stanford University

has a financial relationship (Other) with Daiichi;.
has a financial relationship (Other) with ADCT;.
has a financial relationship (Financial Support) with Seattle Genetics;.
has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with Gilead;.
has a financial relationship (Other) with Epizyme;.
has a financial relationship (Financial Support) with Regeneron;.
has a financial relationship (Other) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Other) with Genentech/Roche;.
has a financial relationship (Financial Support) with Conjupro;.
has a financial relationship (Financial Support) with Cyteir;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Financial Support) with Daiichi;.

Ibrahim Aldoss

has a financial relationship (Professional Services) with Syndax;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Professional Services) with KiTE;.
has a financial relationship (Professional Services) with JAZZ;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Wugen;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Other) with Macrogenics;.

Brian Ball, MD, MS

has a financial relationship (Other) with Rigel;.
has a financial relationship (Other) with Bristol Myers Squibb;.

Rahul Banerjee, MD, FACP

has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Genentech/Roche;.

AJAI CHARI

has no relevant financial relationships to disclose at this time.

Michael Choi, MD

has no relevant financial relationships to disclose at this time.

Catherine Coombs

has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with TG therapeutics;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Independent contractor) with Mingsight;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Allogene;.
has a financial relationship (Independent contractor) with Octapharma;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with MEI Pharma;.
has a financial relationship (Independent contractor) with Genentech;.

Bita Fakhri, Bita Fakhri, MD, MPH

has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Loxo/Lilly;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Adaptive;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with BMS/Juno;.

James Godfrey, MD

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Janssen;.

Murali Janakiram, MBBS MS

has a financial relationship (Independent contractor) with JANNSENN;.

Amrita Krishnan, MD FACP

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Stock) with BMS;.
has a financial relationship (Professional Services) with pfizer;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Janssen;.

Anupama Kumar, M.D.

has no relevant financial relationships to disclose at this time.

Shaji Kumar, MD

has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.
has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.

Michaela Liedtke

has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Nexcella;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Adaptive;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Kite;.

Gabriel Mannis, MD

has a financial relationship (Independent contractor) with Orbital Therapeutics;.
has a financial relationship (Independent contractor) with Servier;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Macrogenics;.
has a financial relationship (Independent contractor) with Immunogen;.
has a financial relationship (Independent contractor) with Stemline;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Rigel;.
has a financial relationship (Independent contractor) with BMS/Celgene;.

Lori Muffly

has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Jasper;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Autolus;.
has a financial relationship (Grant Or Contract) with Kite;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Adaptive;.

Krish Patel, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.

Tycel Phillips, MD

has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Eli Lily;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Independent contractor) with ADCT;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Genmab;.
has a financial relationship (Independent contractor) with Fencer;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Incite;.

Elisa Quiroz

has a financial relationship (Independent contractor) with Guidepoint Consulting ;.

Aaron Rosenberg

has a financial relationship (Grant Or Contract) with Biomea;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Grant Or Contract) with Kangpu;.
has a financial relationship (Grant Or Contract) with BMS;.

Rachel Salit, MD

has a financial relationship (Grant Or Contract) with Incyte Corporation;.

Bart Scott, MD

has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Alexion;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma ;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Janssen ;.
has a financial relationship (Professional Services) with Fate therapeutics;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Stock Options) with Koi Biotherapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Vincerx ;.
has a financial relationship (Professional Services) with Eli Lily ;.

Neil Shah, MD PhD

has a financial relationship (Grant Or Contract) with Bristol-Myers Squibb;.

Geoffrey Shouse, DO, PhD

has a financial relationship (Independent contractor) with Beigene USA;.
has a financial relationship (Independent contractor) with Beigene USA;.
has a financial relationship (Independent contractor) with Kite Pharma;.
has a financial relationship (Independent contractor) with Kite Pharma;.
has a financial relationship (Independent contractor) with Astra Zeneca;.

Surbhi Sidana, MD

has a financial relationship (Professional Services) with Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda;.
has a financial relationship (Grant Or Contract) with Magenta Therapeutics, BMS, Allogene, Janssen;.

Tanya Siddiqi, Medical Director of Lymphoma City of Hope Orange County, Associate Professor, Director of CLL program, Department of Hematology & Hematopoietic Cell Transplantation

has a financial relationship (Independent contractor) with Gilead/Kite;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Abbvie;.

Lili Wang, MD PhD

has no relevant financial relationships to disclose at this time.

Arun Wiita

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Stock) with Indapta Therapeutics;.
Moderator(s)

Aaron Goodman, MD

has a financial relationship (Professional Services) with Seattle Genetics;.

Available Credit

  • 9.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 9.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

BRONZE SPONSORS: 

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.